1. bookVolume 29 (2021): Issue 1 (January 2021)
Journal Details
License
Format
Journal
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
Copyright
© 2020 Sciendo

The positive rate of IgM and IgG antibodies against SARS-CoV-2 is similar in severe and non-severe COVID-19 patients

Published Online: 29 Jan 2021
Page range: 85 - 91
Received: 01 Oct 2020
Accepted: 04 Jan 2021
Journal Details
License
Format
Journal
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
Copyright
© 2020 Sciendo
Abstract

Background: Coronavirus disease 2019 (COVID-19) has spread rapidly in China and globally. In order to control the spread of the epidemic, it is important to find an efficient diagnostic method.

Objectives: The aim of this study was to assess the responses of antibodies during SARS-CoV-2 infection in relation to disease severity and to evaluate the association between the positive rate of antibody detection and nucleic acid test.

Methods: Ninety patients with SARS-CoV-2 infection were recruited in this retrospective observational study. Demographic, clinical data, and SARS-CoV-2 IgM and IgG antibodies in serum specimens were detected at 4 and 6 weeks after diagnosis.

Results: IgM and IgG antibody levels showed a decreased tendency, the titers at week 4 were higher than the titers at week 6: The positive rates of IgM at week 4 and 6 were 92.9% and 67.9%, respectively. The positive rates of IgG at week 4 and week 6 were 100%. No association was found between the positive rate of antibody detection at week 4 or 6 and that of nucleic acid test (P>0.05). No difference between the positive rate of antibodies against SARS-CoV-2 in severe and non-severe COVID-19 patients was observed.

Conclusions: Antibody detection is an effective means in the diagnosis of COVID-19. The titer and positive rate of IgM are lower than those of IgG in the first six weeks after infection. Positive rate of antibodies was not different between severe and non-severe patients.

Keywords

1. Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real estimates of mortality following COVID-19 infection. Lancet Infect Dis. 2020 Jul;20(7):773. DOI: 10.1016/S1473-3099(20)30195-XSearch in Google Scholar

2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb;395(10223):497–506. DOI: 10.1016/S0140-6736(20)30183-5Search in Google Scholar

3. Lee HK, Lee BH, Seok SH, Baek MW, Lee HY, Kim DJ, et al. Production of specific antibodies against SARS-coronavirus nucleocapsid protein without cross reactivity with human coronaviruses 229E and OC43. J Vet Sci. 2010 Jun;11(2):165–7. DOI: 10.4142/jvs.2010.11.2.165Search in Google Scholar

4. National Health Commission of China and State Administration of Traditional Chinese Medicine. Notice on the issuance of strategic guidelines for diagnosis and treatment of novel coronavirus (2019-nCoV) infected pneumonia (seventh edition draft). 2020 Mar. http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.Search in Google Scholar

5. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020 Feb;395(10223):514–23. DOI: 10.1016/S0140-6736(20)30154-9Search in Google Scholar

6. Woo PC, Lau SK, Wong BH, Tsoi HW, Fung AM, Chan KH, et al. Detection of specific antibodies to severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein for serodiagnosis of SARS coronavirus pneumonia. J Clin Microbiol. 2004 May;42(5):2306–9. DOI: 10.1128/JCM.42.5.2306-2309.2004Search in Google Scholar

7. Du Z, Zhu F, Guo F, Yang B, Wang T. Detection of antibodies against SARS-CoV-2 in patients with COVID-19. J Med Virol. 2020 Apr;92(10):1735–8. DOI: 10.1002/jmv.25820Search in Google Scholar

8. Zhou S, Wang Y, Zhu T, Xia L. CT Features of Coronavirus Disease 2019 (COVID-19) Pneumonia in 62 Patients in Wuhan, China. AJR Am J Roentgenol. 2020 Jun;214(6):1287–94. DOI: 10.2214/AJR.20.22975Search in Google Scholar

9. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. Jama. 2020 Mar;323(11):1061–9. DOI: 10.1001/jama.2020.1585Search in Google Scholar

10. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020 Jul;75(7):1730–1741. DOI: 10.1111/all.14238Search in Google Scholar

11. Zha L, Li S, Pan L, Tefsen B, Li Y, French N, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust. 2020 May;212(9):416–20. DOI: 10.5694/mja2.50577Search in Google Scholar

12. Zhang W, Du RH, Li B, Zheng XS, Yang XL, Hu B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect. 2020 Feb;9(1):386–9. DOI: 10.1080/22221751.2020.1729071Search in Google Scholar

13. Hou H, Wang T, Zhang B, Luo Y, Mao L, Wang F, et al. Detection of IgM and IgG antibodies in patients with coronavirus disease 2019. Clin Transl Immunology. 2020 May;9(5):e01136. DOI: 10.1002/cti2.1136Search in Google Scholar

14. Racine R, Winslow GM. IgM in microbial infections: taken for granted? Immunol Lett. 2009 Aug;125(2):79–85. DOI: 10.1016/j.imlet.2009.06.003Search in Google Scholar

15. Jin Y, Wang M, Zuo Z, Fan C, Ye F, Cai Z, et al. Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019. Int J Infect Dis. 2020 May;94:49–52. DOI: 10.1016/j.ijid.2020.03.065Search in Google Scholar

16. Choe JY, Kim JW, Kwon HH, Hong HL, Jung CY, Jeon CH, et al. Diagnostic performance of immunochromatography assay for rapid detection of IgM and IgG in coronavirus disease 2019. J Med Virol. 2020 May;92(11):2567–72. DOI: 10.1002/jmv.26060Search in Google Scholar

Plan your remote conference with Sciendo